A5080900202- Pancreatic and Hepatic Oncology Research
- Cancer Genomics and Diagnostics
- Cancer Treatment and Pharmacology
- Cancer therapeutics and mechanisms
- Epigenetics and DNA Methylation
- Colorectal Cancer Treatments and Studies
- Lung Cancer Treatments and Mutations
- Neuroendocrine Tumor Research Advances
- Cancer, Hypoxia, and Metabolism
- Cancer Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Cancer-related Molecular Pathways
- Advanced Breast Cancer Therapies
- Microtubule and mitosis dynamics
- Monoclonal and Polyclonal Antibodies Research
- Cancer Cells and Metastasis
- Hedgehog Signaling Pathway Studies
- Lung Cancer Research Studies
- Pancreatitis Pathology and Treatment
- Peptidase Inhibition and Analysis
- Chronic Lymphocytic Leukemia Research
- Radiomics and Machine Learning in Medical Imaging
- DNA Repair Mechanisms
- Neuroblastoma Research and Treatments
- HER2/EGFR in Cancer Research
Translational Genomics Research Institute
2016-2025
HonorHealth
2016-2025
City of Hope
2018-2025
Clinical Research Institute
2006-2024
City Of Hope National Medical Center
2019-2024
Translational Research Institute
2023
The University of Texas Health Science Center at Houston
1988-2021
National Institute of Environmental Health Sciences
2021
Asan Medical Center
2021
University of Ulsan
2021
In a phase 1-2 trial of albumin-bound paclitaxel (nab-paclitaxel) plus gemcitabine, substantial clinical activity was noted in patients with advanced pancreatic cancer. We conducted 3 study the efficacy and safety combination versus gemcitabine monotherapy metastatic cancer.We randomly assigned Karnofsky performance-status score 70 or more (on scale from 0 to 100, higher scores indicating better performance status) nab-paclitaxel (125 mg per square meter body-surface area) followed by (1000...
PURPOSE Most patients with advanced pancreas cancer experience pain and must limit their daily activities because of tumor-related symptoms. To date, no treatment has had a significant impact on the disease. In early studies gemcitabine, experienced an improvement in disease-related Based those findings, definitive trial was performed to assess effectiveness gemcitabine newly diagnosed cancer. PATIENTS AND METHODS One hundred twenty-six symptomatic completed lead-in period characterize...
Potential risk factors responsible for development of doxorubicin-induced congestive heart failure were examined through retrospective analysis 4018 patient records. The overall incidence drug-induced was 2.2% (88 cases). probability incurring related to the total dose doxorubicin administered. There a continuum increasing as cumulative amount administered drug increased. A weekly schedule associated with significantly lower than usually employed every 3-week schedule. An increase in...
Taxol is an antitumor agent in clinical trial that has been shown to have activity against advanced ovarian carcinoma and melanoma. Hypersensitivity reactions (HSRs) one of the toxicities observed with administration this drug. Of 301 patients treated, 32 had definite (27 patients) or possible (five hypersensitivity taxol. All but patient reaction from first second exposure agent. Reactions occurred at a variety doses were characterized most frequently by dyspnea, hypotension, bronchospasm,...
Mutations in hedgehog pathway genes, primarily genes encoding patched homologue 1 (PTCH1) and smoothened (SMO), occur basal-cell carcinoma. In a phase clinical trial, we assessed the safety pharmacokinetics of GDC-0449, small-molecule inhibitor SMO, responses metastatic or locally advanced carcinoma to drug.
A targeted nanoparticle containing docetaxel displays antitumor activity in animals and differentiated pharmacological properties patients with advanced solid tumors.
Purpose The trial objectives were to identify the maximum-tolerated dose (MTD) of first-line gemcitabine plus nab-paclitaxel in metastatic pancreatic adenocarcinoma and provide efficacy safety data. Additional evaluate positron emission tomography (PET) scan response, secreted protein acidic rich cysteine (SPARC), CA19-9 levels relation efficacy. Subsequent preclinical studies investigated changes involving stroma drug uptake. Patients Methods with previously untreated advanced cancer...
PURPOSE: To assess the feasibility of administering OSI-774, to recommend a dose on protracted, continuous daily schedule, characterize its pharmacokinetic behavior, and acquire preliminary evidence anticancer activity. PATIENTS AND METHODS: Patients with advanced solid malignancies were treated escalating doses OSI-774 in three study parts (A C) evaluate progressively longer treatment intervals. Part A patients received 25 100 mg once daily, for 3 days each week, weeks every 4 weeks. B...
Medulloblastoma is the most common malignant brain tumor in children. Aberrant activation of hedgehog signaling pathway strongly implicated development some cases medulloblastoma. A 26-year-old man with metastatic medulloblastoma that was refractory to multiple therapies treated a novel inhibitor, GDC-0449; treatment resulted rapid (although transient) regression and reduction symptoms. Molecular analyses specimens obtained before suggested there pathway, loss heterozygosity somatic mutation...
The resistance of tumor cells to chemotherapeutic drugs is a major obstacle successful cancer chemotherapy. In human cells, expression the MDR1 gene, encoding transmembrane efflux pump (P-glycoprotein), leads decreased intracellular accumulation and variety lipophilic (multidrug resistance; MDR). levels MDR in cell lines selected vitro have been shown correlate with steady-state mRNA P-glycoprotein. severalfold increase cellular drug resistance, are close limits detection by conventional...
Background:Positive findings from the phase III MPACT trial led to regulatory approval of nab-paclitaxel plus gemcitabine as a treatment option for patients with metastatic pancreatic cancer. This report is an update overall survival (OS) based on longer follow-up.
Purpose To compare the progression-free survival (PFS) using a treatment regimen selected by molecular profiling (MP) of patient's tumor with PFS for most recent on which patient had experienced progression (ie, as his own control). Patients and Methods refractory metastatic cancer tissue samples submitted MP in two formats including formalin-fixed immunohistochemistry fluorescent situ hybridization assays immediately frozen oligonucleotide microarray (MA) gene expression (all performed...
Pancreatic ductal adenocarcinoma (PDAC) is characterized by high levels of fibrosis, termed desmoplasia, which thought to hamper the efficacy therapeutics treating PDAC. Our primary focus was evaluate differences in extent desmoplasia tumors and metastatic lesions. As burden a cause for mortality PDAC, metastases may help determine whether targeting will benefit patients with late-stage, disease.We sought assess lesions PDAC compare it that tumors. Fifty-three patients' primaries 57 were...
To update a clinical practice guideline on the use of chemotherapy and radiation therapy protectants for patients with cancer.An committee reviewed literature published since last in 2002.Thirty-nine reports met inclusion criteria: palifermin dexrazoxane, three (two studies) each; amifostine, 33 (31 studies); mesna, no randomized trials identified 2002.Dexrazoxane is not recommended routine breast cancer (BC) adjuvant setting, or metastatic setting initial doxorubicin-based chemotherapy....
The hedgehog (Hh) signaling pathway, a key regulator of cell growth and differentiation during development is implicated in pathogenesis certain cancers. Vismodegib (GDC-0449) small-molecule inhibitor smoothened, component Hh signaling. This phase I trial assessed GDC-0449 treatment patients with solid tumors refractory to current therapies or for which no standard therapy existed.Sixty-eight received at 150 mg/d (n = 41), 270 23), 540 4). Adverse events, tumor responses, pharmacokinetics,...
Hallmark deregulated signaling in cancer cells drives excessive ribosome biogenesis within the nucleolus, which elicits unbridled cell growth and proliferation. The rate-limiting step of is synthesis rRNA (building blocks ribosomes) by RNA Polymerase I (Pol I). Numerous kinase pathways products proto-oncogenes can up-regulate Pol I, whereas tumor suppressor proteins inhibit synthesis. In tumorigenesis, activating mutations certain cancer-associated kinases loss-of-function suppressors lead...
Expression of the colony-stimulating factor 1 (CSF1) gene is elevated in most tenosynovial giant-cell tumors. This observation has led to discovery and clinical development therapy targeting CSF1 receptor (CSF1R).Using x-ray co-crystallography guide our drug-discovery research, we generated a potent, selective CSF1R inhibitor, PLX3397, that traps kinase autoinhibited conformation. We then conducted multicenter, phase trial two parts analyze this compound. In first part, evaluated escalations...
Cancer cells expressing PD-1 ligands (PD-L1/PD-L2) inhibit immune-modulatory T-cell activation facilitating disease progression. Preliminary clinical trials exploring interruption of PD-1/PD-L1 signaling showed benefit in several cancer types. We analyzed the distribution PD-1-positive tumor-infiltrating lymphocytes (TIL) and cells' expression PD-L1 a molecularly profiled cohort 437 malignancies (380 carcinomas, 33 sarcomas, 24 melanomas). that presence PD-1(+) TILs significantly varied...
Pancreatic adenocarcinoma has the worst mortality of any solid cancer. In this study, to evaluate clinical implications genomic alterations in tumour type, we perform whole-exome analyses 24 tumours, targeted 77 and use non-invasive approaches examine tumour-specific mutations circulation these patients. These reveal somatic chromatin-regulating genes MLL, MLL2, MLL3 ARID1A 20% patients that are associated with improved survival. We observe potential therapeutic utility over a third cases....